Boisseau William, Darsaut Tim E, Fahed Robert, Drake Brian, Lesiuk Howard, Rempel Jeremy L, O'Kelly Cian J, Chow Michael M C, Iancu Daniela, Roy Daniel, Weill Alain, Klink Ruby, Raymond Jean
From the Department of Radiology (W.B., D.I., D.R., A.W., R.K., J.R.), Service of Neuroradiology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Department of Interventional Neuroradiology (W.B.), Fondation Adolphe de Rothschild, Paris, Ile de France, France.
AJNR Am J Neuroradiol. 2025 Jun 3;46(6):1137-1142. doi: 10.3174/ajnr.A8620.
Flow diversion (FD) has expanded beyond initial indications (proximal carotid artery aneurysms) to include distal circulation aneurysms (on the anterior, middle, or posterior cerebral arteries). Our objective was to examine results obtained from aneurysms in these locations in the Flow Diversion in Intracranial Aneurysm Treatment Trial (FIAT), which compared FD with alternative standard management options (ASMO).
FIAT was an all-inclusive parallel-group 1:1 randomized study comparing FD with 1 of 4 ASMOs (coiling +/- stenting, parent vessel occlusion [PVO], clipping, or observation, prespecified by clinical judgment). The primary safety outcome was death or dependency (mRS >2) at 3 months. The composite primary outcome was "treatment failure," defined as initial failure to treat the aneurysm; aneurysm rupture or retreatment during follow-up; death or dependency (mRS >2); or angiographic residual aneurysm adjudicated by an independent core laboratory at 12 months. This subgroup analysis was not prespecified, and there was no blinding.
Of the 323 patients in FIAT, 46 (14%) with distal circulation aneurysms were randomly allocated: 23 to FD and 23 to ASMO (coiling +/- stenting 16 patients; PVO, 1 patient; clipping, 3 patients; and observation, 3 patients). Death or dependency at 3 months occurred in 1 patient (allocated ASMO). Treatment failures occurred in 6/23 FD-treated patients (26.1%; 95% CI, 12.6%-46.5%) compared with 11/22 patients treated with ASMO (50.0%; 95% CI, 30.7%-69.3%) (risk ratio = 0.52 [0.23-1.17]; = .13). Serious adverse events were similar.
Distal circulation aneurysms treated with FDs in FIAT showed an encouraging trend, but this analysis was underpowered. Further randomized trials are needed.
血流导向(FD)的应用范围已从最初的适应证(颈内动脉近端动脉瘤)扩展至包括远端循环动脉瘤(大脑前动脉、大脑中动脉或大脑后动脉上的动脉瘤)。我们的目的是在颅内动脉瘤治疗血流导向试验(FIAT)中,研究这些部位动脉瘤的治疗结果,该试验将FD与其他标准治疗方案(ASMO)进行了比较。
FIAT是一项全面的平行组1:1随机研究,将FD与4种ASMO之一(根据临床判断预先指定的单纯栓塞+/-支架辅助、载瘤动脉闭塞[PVO]、夹闭或观察)进行比较。主要安全结局是3个月时的死亡或依赖(改良Rankin量表[mRS]>2)。复合主要结局是“治疗失败”,定义为动脉瘤初始治疗失败;随访期间动脉瘤破裂或再次治疗;死亡或依赖(mRS>2);或12个月时由独立核心实验室判定的血管造影显示有残余动脉瘤。该亚组分析未预先设定,且未采用盲法。
在FIAT的323例患者中,46例(14%)患有远端循环动脉瘤并被随机分组:23例接受FD治疗,23例接受ASMO治疗(16例接受单纯栓塞+/-支架辅助;1例接受PVO;3例接受夹闭;3例接受观察)。3个月时1例(分配至ASMO组)出现死亡或依赖。接受FD治疗的23例患者中有6例(26.1%;95%可信区间[CI],12.6%-46.5%)出现治疗失败,而接受ASMO治疗的22例患者中有11例(50.0%;95%CI,30.7%-69.3%)出现治疗失败(风险比=0.52[0.23-1.17];P=0.13)。严重不良事件相似。
FIAT中接受FD治疗的远端循环动脉瘤显示出令人鼓舞的趋势,但该分析的效能不足。需要进一步的随机试验。